Home

MARKSMAN HEALTHCARE | HEOR & RWE SOLUTIONS

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications is a Health Economic and Outcomes Research (HEOR), Medical Writing and Healthcare Analytics consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilise the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, Real Wold Evidence (RWE) and market access support to large and small life science companies. We further provide services pertaining to “Medical Affairs, Medical Devices, Real World Data Curation and Healthcare Analytics”

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

HEOR

Real World Evidence

Medical Affairs

Medical Devices

Evidence Curation

Healthcare Analytics

EMR Services

Competitive Intelligence

LATEST FROM BLOG

10Jan 2023

Meta-analyses summarize data from head-to-head trials to evaluate pairs of treatments that have been directly compared.[1] However, in certain circumstances, multiple therapies are of interest, and no data is available on their direct comparison. In such cases, indirect treatment comparison (ITC) is performed for synthesizing evidence surrounding treatments of interest.[2] ITC assumes that the studies […]

02Jan 2023

Improvements in healthcare digitalization and accelerated regulatory approvals of novel interventions have boosted the possibilities for gathering real-world data (RWD) and using the resultant real-world evidence (RWE) to support the generalizability, efficacy, and safety of interventions and medical devices, assisting healthcare decision-makers and policymakers.[1-5] RWE helps establish clinical guidelines, perform risk assessment for medication safety, […]

28Dec 2022

When seeking answers to clinical questions about efficacy or other aspects of a proposed intervention, health professionals often look for reliable evidence. Systematic literature reviews (SLRs) serve this purpose, by virtue of their ability to generate high-quality, verifiable, and trustworthy evidence in a systematic, transparent, and impartial manner.(1) In the new evidence pyramid, systematic reviews […]

OUR REPRESENTATIONS

  • ISPOR 2022, May 15-18, Washington DC, USA

  • DIA 2022, June 19-23, Global Annual Meeting, Chicago, USA

  • ASCO 2022, June 3-7, Annual Meeting, Chicago, USA

  • 10X The Medical Device Conference 2022, May 10-12, California, USA